Beijing ACCB Biotech Ltd.
ACCB is a Biotech company with 12 years experiences on molecular diagnostics by providing IVD products&clinical diagnostic services for precision medicine in oncology. We commercializes IVD kits, medical devices and data management software with a complete value chain from R&D, manufacturing, registration to marketing and sales.
ACCB has a 35000sq.ft GMP facility with ISO13485 approved, and a state certified clinical lab with an integrated molecular pathology platform (RT-PCR, NGS, FISH, IHC, etc)
ACCB's sister company is CureSeq, Inc. CureSeq’s mission is to revolutionize next-generation sequencing in the oncology space by making it affordable, offering faster time to results with a comprehensive solution using our products and services. Using our 3-day turnaround test run in our CAP/CLIA certified high complexity molecular lab, our NGS 25 Gene Pan Cancer Panel offers the best results for tumor profiling. CureSeq provides a variety of clinical trial services ranging from Phase I-IV.
Business Needs: Investor
Products to be exported: Biomark XP (qPCR based detection series):
1. Human KRAS Gene Mutation Detection Kit (CE);
2. Human EGFR Gene Mutations Detection Kit (CE);
3. Human BRAF Gene Mutation Detection Kit (CE);
4. Human PIK3CA Gene Mutation Detection Kit (CE);
5. Human KRAS Gene Codons 12/13/61 Mutation Detection Kit;
6. Human CKIT Gene D816V Gene Mutation Detection Kit;
7. Human EML4-ALK Fusion Gene Detection Kit;
8. Human ROS1 Gene Fusion Detection Kit;
9. Human KIF5B-RET Gene Fusion Detection Kit.